Title:
Hysterics Londe methylase inhibitor
Document Type and Number:
Japanese Patent JP6276378
Kind Code:
B2
Abstract:
The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase enzymes. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Inventors:
Kanouni, Tofique
Nie, Choi
Stafford, Jeffrey, Alan
Vir, james, marvin
Nie, Choi
Stafford, Jeffrey, Alan
Vir, james, marvin
Application Number:
JP2016502219A
Publication Date:
February 07, 2018
Filing Date:
March 13, 2014
Export Citation:
Assignee:
Celgene Quantisell Research, Inc.
International Classes:
C07D401/04; A61K31/4439; A61K31/444; A61K31/4545; A61K31/4709; A61K31/5377; A61P35/00; A61P43/00; C07D401/14; C07D405/14; C07D413/14
Domestic Patent References:
| JP2012532861A |
Foreign References:
| WO2011089995A1 | ||||
| WO2012152208A1 | ||||
| WO2008029825A1 | ||||
| WO2012052390A1 | ||||
| WO2010043866A2 |
Other References:
SUZUKI, T. et al.,Rapid Discovery of Highly Potent and Selective Inhibitors of Histone Deacetylase 8 Using Click Chemistry to Generate Candidate Libraries,Journal of Medicinal Chemistry,2012年,55(22),pp. 9562-9575
ONTORIA, J. M. et al.,Identification of Novel, Selective, and Stable Inhibitors of Class II Histone Deacetylases. Validation Studies of the Inhibition of the Enzymatic Activity of HDAC4 by Small Molecules as a Novel Approach for Cancer Therapy,Journal of Medicinal Chemistry,2009年,52(21),pp. 6782-6789
ONTORIA, J. M. et al.,Identification of Novel, Selective, and Stable Inhibitors of Class II Histone Deacetylases. Validation Studies of the Inhibition of the Enzymatic Activity of HDAC4 by Small Molecules as a Novel Approach for Cancer Therapy,Journal of Medicinal Chemistry,2009年,52(21),pp. 6782-6789
Attorney, Agent or Firm:
Kazuhiro Kiyohara